Intec Pharma Ltd. is a late-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company’s product pipeline currently includes product candidates in various clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, is being evaluated in a U.S. Phase III clinical trial as a treatment for Parkinson’s disease symptoms in advanced Parkinson’s disease patients; Accordion Pill Zaleplon, or AP-ZP, is being developed as a treatment for insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers and an Accordion Pill for cannabinoid therapies, or AP-CBD/THC, is expected to initiate clinical trials for a pain indication in the first quarter of 2017.
For share performance and additional information published in the TASE, use the following Link.
Investor relations: AFields@lhai.com